ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
CStone Pharmaceuticals Announces Updated Results from Two Studies of Its Anti-PD-L1 Monoclonal Antibody Sugemalimab (CS1001) At 2020 CSCO Annual Meeting
September 27, 2020CStone Pharmaceuticals (Suzhou) Co., Ltd. announced the updated results from two studies of its anti-PD-L1 monoclonal antibody sugemalimab (CS1001) at the 2020 Chinese Society of Clinical Oncology (CSCO) Annual Meeting. -
CStone submits an abstract on CS1001-201 trial to 2019 ASH Annual Meeting
August 21, 2019The CS1001-201 trial reported in the abstract is a single-arm, multi-centre Phase II clinical study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of CS1001 monotherapy in relapsed or refractory extranodal natural killer (
Pharma Sources Insight January 2025
